- Seasonal influenza activity is currently high across the United States.
- In the 2022-2023 season, there have been at least 13 million illnesses, 120,000 hospitalizations, and 7,300 deaths from influenza.
- The availability of oseltamivir (generic or Tamiflu) may be limited in some communities.
- Antiviral treatment of influenza is important and can reduce the duration of symptoms and the risk of complications.
- Four FDA-approved prescription antiviral medications are available for early treatment of outpatients with influenza.
- The clinical benefit of antiviral treatment is greatest when treatment is started early, within 2 days of illness onset.
- Oseltamivir treatment is recommended for suspected or confirmed influenza requiring hospitalization and for controlling institutional influenza outbreaks.
- Influenza testing, especially rapid molecular assays, can inform antiviral treatment decisions, particularly when other respiratory viruses are also circulating.
- Annual influenza vaccination is recommended for everyone aged 6 months and older as the first and most important tool for preventing influenza.